All In Biotech

Drug Trial Radar · NCT07668180

A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
HK inno.N CorporationIndustry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.

Conditions

  • Sarcopenia in Elderly

Interventions

  • IN-207907 120 mgDrug

    IN-207907 120 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

  • IN-207907 240 mgDrug

    IN-207907 240 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

  • IN-207907 360 mgDrug

    IN-207907 360 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

  • PlaceboDrug

    Placebo will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Short Physical Performance Battery (SPPB) total scoreTime frame: From baseline to week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.